AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Shareholder_NN
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
127_CD
Shareholder_NN
Information_NOMZ
AstraZeneca_NN
1999 2000 2001 2002_CD
2003_CD
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
At_PIN
year_NN
end_NN
1,775_CD
1,766_CD
1,745_CD
1,719_CD
1,693_CD
Weighted_VBN
average_NN
for_PIN
year_NN
1,776_CD
1,768_CD
1,758_CD
1,733_CD
1,709_CD
Stock_NN
market_NN
price_NN
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
Highest_NN
pence_NN
2946 3600 3555 3625_CD
2868_CD
Lowest_NN
pence_NN
2208 1926 2880 1799_CD
1820_CD
At_PIN
year_NN
end_NN
pence_NN
2568 3375 3098 2220_CD
2680_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
before_IN
exceptional_JJ
items_NN
$_$
1.63_CD
$_$
1.62_CD
$_$
1.73_CD
$_$
1.84_CD
$_$
1.78_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
basic_JJ
$_$
0.73_CD
$_$
1.30_CD
$_$
1.65_CD
$_$
1.64_CD
$_$
1.78_CD
Earnings_GER
per_PIN
$_$
0.25_CD
Ordinary_NN
Share_NN
diluted_VBD
$_$
0.73_CD
$_$
1.30_CD
$_$
1.65_CD
$_$
1.64_CD
$_$
1.78_CD
Dividends_NN
$_$
0.70_CD
$_$
0.70_CD
$_$
0.70_CD
$_$
0.70_CD
$_$
0.795_CD
For_PIN
the_DT
period_NN
1_CD
January_NN
1999_CD
to_PIN
31_CD
December_NN
1999_CD
except_PIN
for_PIN
stock_NN
market_NN
prices_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
for_PIN
the_DT
period_NN
from_PIN
6_CD
April_NN
1999_CD
to_PIN
31_CD
December_NN
1999_CD
._.
In_CONJ
addition_NULL
,_,
shareholders_NN
received_VBD
a_DT
distribution_NOMZ
of_PIN
shares_NN
in_PIN
Syngenta_NN
AG_NN
as_IN
a_DT
dividend_NN
in_PIN
specie_NN
in_PIN
respect_NN
of_PIN
the_DT
demerger_NN
of_PIN
Zeneca_NN
Agrochemicals_NN
._.
Zeneca_NN
1999_CD
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
At_PIN
period_NN
end_NN
953_CD
Weighted_JJ
average_NN
for_PIN
period_NN
951_CD
Stock_NN
market_NN
price_NN
per_PIN
25_CD
pence_NN
Ordinary_NN
Share_NN
Highest_NN
pence_NN
3037_CD
Lowest_NN
pence_NN
2406_CD
At_PIN
period_NN
end_NN
pence_NN
3037_CD
For_PIN
the_DT
period_NN
from_PIN
1_CD
January_NN
1999_CD
to_PIN
6_CD
April_NN
1999_CD
Astra_NN
1999_CD
Ordinary_NN
Shares_NN
in_PIN
issue_NN
millions_NN
At_PIN
period_NN
end_NN
1,643_CD
Weighted_VBN
average_NN
for_PIN
period_NN
1,643_CD
Stock_NN
market_NN
price_NN
per_PIN
Astra_NN
A_NN
Share_NN
Highest_NN
SEK_NN
190_CD
Lowest_NN
SEK_NN
154_CD
At_PIN
period_NN
end_NN
SEK_NN
190_CD
Stock_NN
market_NN
price_NN
per_PIN
Astra_NN
B_NN
Share_NN
Highest_NN
SEK_NN
190_CD
Lowest_NN
SEK_NN
154_CD
At_PIN
period_NN
end_NN
SEK_NN
190_CD
For_PIN
the_DT
period_NN
from_PIN
1_CD
January_NN
1999_CD
to_PIN
6_CD
April_NN
1999_CD
Percentage_NN
analysis_NN
at_PIN
31_CD
December_NN
2003_CD
of_PIN
issued_VBN
share_NN
capital_NN
By_PIN
size_NN
of_PIN
account_NN
2003_CD
No._NN
._.
In_CONJ
addition_NULL
,_,
there_EX
were_VBD
approximately_RB
41,000_CD
holders_NN
of_PIN
American_JJ
Depositary_NN
Receipts_NN
ADRs_NN
representing_VBG [WZPRES]
7.53_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
and_CC
161,000_CD
holders_NN
of_PIN
shares_NN
held_VBN [PRIV]
under_IN
the_DT
VPC_NN
Services_NN
Agreement_NOMZ
representing_VBG [WZPRES]
22.13_CD
%_NN
of_PIN
the_DT
issued_VBN
share_NN
capital_NN
._.
The_DT
ADRs_NN
,_,
each_QUAN
of_PIN
which_WDT [PIRE]
is_VPRT [BEMA]
equivalent_PRED
to_PIN
one_CD
Ordinary_NN
Share_NN
,_,
are_VPRT [BYPA]
issued_VBN
by_PIN
JPMorgan_NN
Chase_NN
Bank_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Shareholder_NN
Information_NOMZ
128_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Shareholder_NN
Information_NOMZ
continued_VBD
AstraZeneca_NN
PLC_NN
Since_OSUB
April_NN
1999_CD
,_,
following_VBG [PRESP]
the_DT
AstraZeneca_NN
merger_NN
,_,
the_DT
principal_JJ
markets_NN
for_PIN
trading_GER
in_PIN
the_DT
shares_NN
of_PIN
AstraZeneca_NN
PLC_NN
are_VPRT [BEMA]
the_DT
London_NN
,_,
Stockholm_NN
and_PHC
New_NN
York_NN
Stock_NN
Exchanges_NN
._.
The_DT
table_NN
below_PLACE
sets_NN
forth_RB
,_,
for_PIN
the_DT
four_CD
quarters_NN
of_PIN
2002_CD
and_CC
for_PIN
the_DT
first_JJ
two_CD
quarters_NN
and_CC
last_JJ
six_CD
months_NN
of_PIN
2003_CD
the_DT
reported_VBN [PUBV]
high_JJ
and_PHC
low_JJ
share_NN
prices_NN
of_PIN
AstraZeneca_NN
PLC_NN
,_,
on_PIN
the_DT
following_VBG
bases_NN
:_:
for_PIN
shares_NN
listed_VBN [WZPAST]
on_PIN
the_DT
London_NN
Stock_NN
Exchange_NN
LSE_NN
the_DT
reported_VBN [PUBV]
high_JJ
and_PHC
low_JJ
middle_JJ
market_NN
closing_VBG [WZPRES]
quotations_NOMZ
are_VPRT [PASS]
derived_VBN
from_PIN
The_DT
Daily_NN
Official_NN
List_NN
:_:
for_PIN
shares_NN
listed_VBN [WZPAST]
on_PIN
the_DT
Stockholm_NN
Stock_NN
Exchange_NN
SSE_NN
the_DT
high_JJ
and_PHC
low_JJ
closing_GER
sales_NN
prices_NN
are_VPRT
as_IN
stated_VBN [PUBV]
in_PIN
the_DT
Official_NN
List_NN
:_:
for_PIN
American_JJ
Depositary_NN
Shares_NN
ADS_NN
listed_VBN [WZPAST]
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
the_DT
reported_VBN [PUBV]
high_JJ
and_PHC
low_JJ
sales_NN
prices_NN
are_VPRT
as_IN
reported_VBN [PUBV]
by_PIN
Dow_NN
Jones_NN
ADR_NN
quotations_NOMZ
._.
The_DT
average_JJ
price_NN
paid_VBN [WZPAST]
per_PIN
share_NN
in_PIN
2003_CD
was_VBD [BEMA]
2535_CD
pence_NN
._.
Between_PIN
1999_CD
and_CC
2002_CD
a_DT
total_NN
of_PIN
65.6_CD
million_CD
Ordinary_NN
Shares_NN
were_VBD [BEMA]
re-purchased_PRED
,_,
and_ANDC
subsequently_TIME
canceled_VBN
,_,
at_PIN
an_DT
average_JJ
price_NN
of_PIN
2856_CD
pence_NN
per_PIN
share_NN
for_PIN
a_DT
consideration_NOMZ
,_,
including_VBG
expenses_NN
,_,
of_PIN
$_$
2,805_CD
m._FW
The_DT
excess_NN
of_PIN
the_DT
consideration_NOMZ
over_IN
the_DT
nominal_JJ
value_NN
was_VBD [PASS]
charged_VBN
against_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
reserve_NN
._.
Shares_NN
issued_VBD
in_PIN
respect_NN
of_PIN
share_NN
schemes_NN
totalled_VBD
1.2_CD
million_CD
._.
In_PIN
1999_CD
in_PIN
connection_NOMZ
with_PIN
the_DT
merger_NN
,_,
AstraZenecas_NN
share_NN
capital_NN
was_VBD [PASS]
redenominated_VBN
into_PIN
US_FPP1
dollars_NN
._.
On_PIN
6_CD
April_NN
1999_CD
,_,
Zeneca_NN
shares_NN
were_VBD [PASS]
canceled_VBN
and_CC
US_FPP1
dollar_NN
shares_NN
issued_VBN
,_,
credited_VBN
as_IN
fully_AMP
paid_VBN
on_PIN
the_DT
basis_NN
of_PIN
one_CD
dollar_NN
share_NN
for_PIN
each_QUAN
Zeneca_NN
share_NN
then_RB
held_VBD [PRIV]
._.
This_DEMP
was_VBD [BYPA]
achieved_VBN
by_PIN
a_DT
reduction_NOMZ
of_PIN
capital_NN
under_IN
section_NOMZ
135_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Upon_PIN
the_DT
reduction_NOMZ
of_PIN
capital_NN
becoming_VBG [WZPRES]
effective_JJ
,_,
all_QUAN
issued_VBN
and_PHC
unissued_VBN
Zeneca_NN
shares_NN
were_VBD [PASS]
canceled_VBN
and_CC
the_DT
sum_NN
arising_VBG [WZPRES]
as_CONJ
a_NULL
result_NULL
thereof_RB
credited_VBD
to_PIN
a_DT
special_JJ
reserve_NN
which_WDT [WHSUB]
was_VBD [PASS]
converted_VBN
into_PIN
US_FPP1
dollars_NN
at_PIN
the_DT
rate_NN
of_PIN
exchange_NN
prevailing_VBG [WZPRES]
on_PIN
the_DT
record_NN
date_NN
._.
This_DEMO
US_FPP1
dollar_NN
reserve_NN
was_VBD [SPAU] [PASS]
then_RB
applied_VBN
in_PIN
paying_VBG
up_RP
at_PIN
par_JJ
newly_RB
created_VBN
US_FPP1
dollar_NN
shares_NN
._.
At_PIN
the_DT
same_JJ
time_NN
as_IN
the_DT
US_FPP1
dollar_NN
shares_NN
were_VBD [PASS]
issued_VBN
,_,
the_DT
Company_NN
issued_VBN
50,000_CD
Redeemable_JJ
Preference_NN
Shares_NN
for_PIN
cash_NN
at_PIN
par_NN
._.
The_DT
Redeemable_JJ
Preference_NN
Shares_NN
carry_VPRT
limited_JJ
class_NN
voting_NN
rights_NN
and_CC
no_SYNE
dividend_NN
rights_NN
._.
This_DEMO
class_NN
of_PIN
shares_NN
is_VPRT [BEMA]
also_RB
capable_PRED
of_PIN
redemption_NOMZ
at_PIN
par_NN
at_PIN
the_DT
option_NOMZ
of_PIN
the_DT
Company_NN
on_PIN
the_DT
giving_VBG
of_PIN
seven_CD
days_NN
written_VBN [PUBV]
notice_NN
to_PIN
the_DT
registered_VBN
holder_NN
of_PIN
the_DT
shares_NN
._.
A_DT
total_NN
of_PIN
826_CD
million_CD
AstraZeneca_NN
shares_NN
were_VBD [PASS]
issued_VBN
to_PIN
Astra_NN
shareholders_NN
who_WP [WHSUB]
accepted_VBD [PRIV]
the_DT
merger_NN
offer_NN
before_IN
the_DT
final_JJ
closing_GER
date_NN
,_,
21_CD
May_POMD
1999_CD
._.
AstraZeneca_NN
received_VBD
acceptances_NN
from_PIN
Astra_NN
shareholders_NN
representing_VBG [WZPRES]
99.6_CD
per_PIN
cent_NN
of_PIN
Astras_NN
shares_NN
and_CC
the_DT
remaining_VBG
0.4_CD
per_PIN
cent_NN
was_VBD [PASS]
acquired_VBN
in_PIN
2000_CD
for_PIN
cash_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Shareholder_NN
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
129_CD
Major_JJ
shareholdings_GER
On_PIN
28_CD
January_NN
2004_CD
the_DT
following_GER
had_VBD [PEAS]
disclosed_VBN [PUBV]
an_DT
interest_NN
in_PIN
the_DT
issued_VBN
Ordinary_NN
Share_NN
capital_NN
of_PIN
the_DT
Company_NN
in_PIN
accordance_NN
with_PIN
the_DT
requirements_NOMZ
of_PIN
Sections_NOMZ
198-208_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
:_:
Date_NN
of_PIN
Percentage_NN
disclosure_NN
of_PIN
issued_VBN
Shareholder_NN
Number_NN
of_PIN
shares_NN
to_PIN
Company_NN
share_NN
capital_NN
The_DT
Capital_NN
Group_NN
Companies_NN
,_,
Inc._NN
254,143,676_CD
23_CD
Jan_NN
2004_CD
15.01_CD
%_NN
Investor_NN
AB_NN
91,545,308_CD
16_CD
Apr_NN
1999_CD
5.41_CD
%_NN
Putnam_NN
Investment_NOMZ
Management_NOMZ
,_,
LLC_NN
and_CC
The_DT
Putnam_NN
Advisory_NN
Company_NN
,_,
LLC_NN
52,643,485_CD
8_CD
Feb_NN
2002_CD
3.11_CD
%_NN
Legal_NN
&_CC
General_NN
Investment_NOMZ
Management_NOMZ
Limited_NN
52,518,020_CD
13_CD
Jun_NN
2002_CD
3.10_CD
%_NN
No_SYNE
other_JJ
person_NN
held_VBD [PRIV]
a_DT
notifiable_JJ
interest_NN
in_PIN
shares_NN
,_,
comprising_VBG [PRESP]
3_CD
%_NN
or_CC
more_EMPH
of_PIN
the_DT
issued_VBN
Ordinary_NN
Share_NN
capital_NN
of_PIN
the_DT
Company_NN
,_,
appearing_VBG [SMP] [PRESP]
in_PIN
the_DT
register_NN
of_PIN
interests_NN
in_PIN
shares_NN
maintained_VBN [PUBV]
under_IN
the_DT
provisions_NN
of_PIN
Section_NOMZ
211_CD
of_PIN
the_DT
Companies_NN
Act_NN
1985_CD
._.
Since_OSUB
the_DT
date_NN
of_PIN
disclosure_NN
to_PIN
the_DT
Company_NN
,_,
the_DT
interest_NN
of_PIN
any_QUAN
person_NN
listed_VBN
above_PLACE
in_PIN
the_DT
Ordinary_NN
Shares_NN
of_PIN
the_DT
Company_NN
may_POMD
have_VB [PEAS]
increased_VBN
or_CC
decreased_VBN
._.
No_SYNE
requirement_NOMZ
to_TO
notify_VB
the_DT
Company_NN
of_PIN
any_QUAN
increase_NN
or_CC
decrease_NN
would_PRMD
have_VB [PEAS]
arisen_VBN
unless_COND
the_DT
holding_VBG [PRIV]
moved_VBD [SUAV]
up_RP
or_CC
down_RP
through_PIN
a_DT
whole_JJ
number_NN
percentage_NN
level_NN
._.
The_DT
percentage_NN
level_NN
may_POMD
increase_VB
on_PIN
the_DT
cancellation_NOMZ
of_PIN
shares_NN
following_VBG [WZPRES]
a_DT
re-purchaseof_JJ
shares_NN
under_IN
the_DT
Companys_NN
share_NN
re-purchase_JJ
program_NN
or_CC
decrease_NN
on_PIN
the_DT
issue_NN
of_PIN
new_JJ
shares_NN
under_IN
any_QUAN
of_PIN
the_DT
Companys_NN
share_NN
plans_NN
._.
Significant_JJ
changes_NN
in_PIN
the_DT
percentage_NN
ownership_NN
held_VBN [PRIV] [WZPAST]
by_PIN
major_JJ
shareholders_NN
during_PIN
the_DT
past_JJ
three_CD
years_NN
are_VPRT [PASS]
set_VBN
out_PIN
below_PLACE
._.
Major_JJ
shareholders_NN
do_VPRT
not_XX0
have_VB
different_JJ
voting_NN
rights_NN
._.
Percentage_NN
of_PIN
issued_VBN
share_NN
capital_NN
Shareholder_NN
28_CD
Jan_NN
2004_CD
29_CD
Jan_NN
2003_CD
17_CD
Feb_NN
2002_CD
9_CD
Feb_NN
2001_CD
The_DT
Capital_NN
Group_NN
Companies_NN
,_,
Inc._NN
15.01_CD
%_NN
11.92_CD
%_NN
11.09_CD
%_NN
10.02_CD
%_NN
Investor_NN
AB_NN
5.41_CD
%_NN
5.33_CD
%_NN
5.25_CD
%_NN
5.18_CD
%_NN
Putnam_NN
Investment_NOMZ
Management_NOMZ
,_,
LLC_NN
and_CC
The_DT
Putnam_NN
Advisory_NN
Company_NN
,_,
LLC_NN
3.11_CD
%_NN
3.06_CD
%_NN
3.02_CD
%_NN
3.00_CD
%_NN
Legal_NN
&_CC
General_NN
Investment_NOMZ
Management_NOMZ
Limited_NN
3.10_CD
%_NN
3.06_CD
%_NN
3.00_CD
%_NN
3.00_CD
%_NN
AstraZeneca_NN
PLC_NN
American_NN
Depositary_NN
Shares_NN
each_QUAN
representing_VBG
one_CD
Ordinary_NN
Share_NN
evidenced_VBD
by_PIN
American_JJ
Depositary_NN
Receipts_NN
issued_VBN [WZPAST]
by_PIN
JPMorgan_NN
Chase_NN
Bank_NN
,_,
as_IN
depositary_JJ
,_,
are_VPRT [PASS]
listed_VBN
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
._.
As_IN
of_PIN
28_CD
January_NN
2004_CD
,_,
the_DT
proportion_NOMZ
of_PIN
Ordinary_NN
Shares_NN
represented_VBN [WZPAST]
by_PIN
American_JJ
Depositary_NN
Shares_NN
was_VBD [BEMA]
7.55_CD
%_NN
of_PIN
the_DT
Ordinary_NN
Shares_NN
outstanding_JJ
._.
Number_NN
of_PIN
registered_VBN
holders_NN
of_PIN
Ordinary_NN
Shares_NN
as_IN
of_PIN
28_CD
January_NN
2004_CD
:_:
In_PIN
the_DT
US_FPP1
849_CD
Total_JJ
169,520_CD
Number_NN
of_PIN
record_NN
holders_NN
of_PIN
American_JJ
Depositary_NN
Receipts_NN
as_IN
of_PIN
28_CD
January_NN
2004_CD
:_:
In_PIN
the_DT
US_FPP1
3,045_CD
Total_JJ
3,077_CD
So_RB
far_PLACE
as_IN
the_DT
Company_NN
is_VPRT [BEMA]
aware_PRED
,_,
it_PIT
is_VPRT [BEMA]
neither_SYNE
directly_RB
nor_SYNE
indirectly_RB
owned_VBN
nor_SYNE
controlled_VBN
by_PIN
one_CD
or_CC
more_EMPH
corporations_NOMZ
or_CC
by_PIN
any_QUAN
government_NOMZ
._.
As_IN
of_PIN
28_CD
January_NN
2004_CD
,_,
the_DT
total_JJ
amount_NN
of_PIN
the_DT
Companys_NN
voting_NN
securities_NOMZ
owned_VBN [WZPAST]
by_PIN
Directors_NN
and_PHC
Officers_NN
of_PIN
the_DT
Company_NN
was_VBD
:_:
Title_NN
of_PIN
class_NN
Amount_NN
owned_VBD
Percent_NN
of_PIN
class_NN
$_$
0.25_CD
shares_NN
Ordinary_NN
Shares_NN
454,319_CD
0.03_CD
%_NN
The_DT
Company_NN
does_VPRT
not_XX0
know_VB [PRIV]
of_PIN
any_QUAN
arrangements_NOMZ
,_,
the_DT
operation_NOMZ
of_PIN
which_WDT [PIRE]
might_POMD
result_VB
in_PIN
a_DT
change_NN
in_PIN
the_DT
control_NN
of_PIN
the_DT
Company_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Shareholder_NN
Information_NOMZ
130_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Shareholder_NN
Information_NOMZ
continued_VBD
Related_JJ
party_NN
transactions_NOMZ
During_PIN
the_DT
period_NN
1_CD
January_NN
2004_CD
to_PIN
28_CD
January_NN
2004_CD
,_,
there_EX
were_VBD
no_SYNE
transactions_NOMZ
,_,
loans_NN
,_,
or_CC
proposed_VBN [SUAV]
transactions_NOMZ
between_PIN
the_DT
Company_NN
and_CC
any_QUAN
related_JJ
parties_NN
which_WDT [WHSUB]
were_VBD
material_NN
to_TO
either_CC
the_DT
Company_NN
or_CC
the_DT
related_JJ
party_NN
,_,
or_CC
which_WDT
were_VBD [BEMA]
unusual_PRED
in_PIN
their_TPP3
nature_NN
or_CC
conditions_NOMZ
._.
See_VB [PRIV]
also_RB
Note_VB [PRIV]
33_CD
Statutory_NN
and_CC
other_JJ
information_NOMZ
._.
Options_NOMZ
to_TO
purchase_VB
securities_NOMZ
from_PIN
registrant_JJ
or_CC
subsidiaries_NN
a_DT
As_IN
of_PIN
28_CD
January_NN
2004_CD
,_,
options_NOMZ
outstanding_JJ
to_TO
subscribe_VB
for_PIN
Ordinary_NN
Shares_NN
of_PIN
$_$
0.25_CD
of_PIN
the_DT
Company_NN
were_VBD
:_:
Number_NN
of_PIN
shares_NN
Subscription_NOMZ
price_NN
Normal_JJ
expiry_NN
date_NN
47,628,173_CD
748p3487p_CD
20042013_CD
The_DT
weighted_JJ
average_JJ
subscription_NOMZ
price_NN
of_PIN
options_NOMZ
outstanding_JJ
at_PIN
28_CD
January_NN
2004_CD
was_VBD [BEMA]
2763p_PRED
._.
All_QUAN
options_NOMZ
were_VBD [PASS]
granted_VBN [SUAV]
under_IN
Company_NN
employee_NN
schemes_NN
._.
b_NN
Included_VBN [WZPAST]
in_PIN
paragraph_NN
a_DT
are_VPRT [PASS]
options_NOMZ
granted_VBN [SUAV] [WZPAST]
to_PIN
Directors_NN
and_PHC
Officers_NN
of_PIN
AstraZeneca_NN
as_IN
follows_VPRT
:_:
Number_NN
of_PIN
shares_NN
Subscription_NOMZ
price_NN
Normal_JJ
expiry_NN
date_NN
1,943,103_CD
891p3487p_CD
20052013_CD
c_NN
Included_VBN [WZPAST]
in_PIN
paragraph_NN
b_NN
are_VPRT [PASS]
options_NOMZ
granted_VBN [SUAV]
to_TO [SPIN]
individually_RB
named_VBN
Directors_NN
._.
Details_NN
of_PIN
these_DEMO
option_NOMZ
holdings_GER
as_IN
at_PIN
31_CD
December_NN
2003_CD
are_VPRT [PASS]
shown_VBN [PRIV]
in_PIN
the_DT
Directors_NN
Remuneration_NOMZ
Report_NN
._.
During_PIN
the_DT
period_NN
1_CD
January_NN
2004_CD
to_PIN
28_CD
January_NN
2004_CD
,_,
no_SYNE
Director_NN
exercised_VBN
any_QUAN
options_NOMZ
._.
Dividend_NN
payments_NOMZ
The_DT
record_NN
date_NN
for_PIN
the_DT
second_JJ
interim_JJ
dividend_NN
for_PIN
2003_CD
payable_JJ
on_PIN
6_CD
April_NN
2004_CD
in_PIN
the_DT
UK_NN
,_,
the_DT
US_FPP1
and_PHC
Sweden_NN
is_VPRT [BEMA]
20_CD
February_NN
2004_CD
._.
Shares_NN
trade_NN
ex-dividend_NN
on_PIN
the_DT
London_NN
and_PHC
Stockholm_NN
Stock_NN
Exchanges_NN
from_PIN
18_CD
February_NN
2004_CD
and_CC
ADRs_NN
trade_NN
ex-dividend_NN
on_PIN
the_DT
New_NN
York_NN
Stock_NN
Exchange_NN
from_PIN
the_DT
same_JJ
date_NN
._.
From_PIN
2004_CD
,_,
dividends_NN
will_PRMD [SPAU]
normally_RB
be_VB [PASS]
paid_VBN
as_IN
follows_VPRT
:_:
First_NN
interim_JJ
:_:
Announced_JJ
end_NN
of_PIN
July_NN
and_CC
paid_VBN
in_PIN
September_NN
Second_NN
interim_NN
:_:
Announced_JJ
end_NN
of_PIN
January_NN
and_CC
paid_VBN
in_PIN
March_NN
The_NN
record_NN
date_NN
for_PIN
the_DT
first_JJ
interim_JJ
dividend_NN
for_PIN
2004_CD
payable_JJ
on_PIN
20_CD
September_NN
2004_CD
in_PIN
the_DT
UK_NN
,_,
the_DT
US_FPP1
and_PHC
Sweden_NN
is_VPRT [BEMA]
13_CD
August_NN
2004_CD
._.
Shareview_NN
AstraZenecas_NN
shareholders_NN
with_PIN
internet_NN
access_NN
may_POMD
visit_VB
www_NN
._.
co._FW
uk_FW
and_CC
register_VB
their_TPP3
details_NN
to_TO
create_VB
a_DT
portfolio_NN
._.
Shareview_NN
is_VPRT [BEMA]
a_DT
free_JJ
and_PHC
secure_JJ
on-line_JJ
service_NN
from_PIN
Lloyds_NN
TSB_NN
Registrars_NN
that_TSUB
gives_VPRT
access_NN
to_PIN
shareholdings_GER
including_VBG [WZPRES]
balance_NN
movements_NOMZ
,_,
indicative_JJ
share_NN
prices_NN
and_PHC
information_NOMZ
about_IN
recent_JJ
dividends_NN
._.
ShareGift_NN
AstraZeneca_NN
welcomes_VPRT
and_PHC
values_VPRT
all_QUAN
its_PIT
shareholders_NN
,_,
no_SYNE
matter_NN
how_RB
many_QUAN
or_CC
how_RB
few_QUAN
shares_NN
they_TPP3
own_VPRT
._.
However_CONJ
,_,
shareholders_NN
who_WP [WHSUB]
have_VPRT
only_DWNT
a_DT
small_JJ
number_NN
of_PIN
shares_NN
whose_WPS [WHOBJ]
value_NN
makes_VPRT
it_PIT
uneconomic_JJ
to_TO
sell_VB
them_TPP3
,_,
either_RB
now_TIME
or_CC
at_PIN
some_QUAN
stage_NN
in_PIN
the_DT
future_NN
,_,
may_POMD
wish_VB
to_TO
consider_VB [PRIV]
donating_VBG
them_TPP3
to_PIN
charity_NOMZ
through_PIN
ShareGift_NN
,_,
an_DT
independent_JJ
charity_NOMZ
share_NN
donation_NOMZ
scheme_NN
._.
One_CD
of_PIN
the_DT
advantages_NN
of_PIN
the_DT
scheme_NN
is_VPRT
that_DEMO
there_EX
is_VPRT
no_SYNE
gain_NN
or_CC
loss_NN
for_PIN
capital_NN
gains_NN
tax_NN
purposes_NN
on_PIN
gifts_NN
of_PIN
shares_NN
through_PIN
ShareGift_NN
and_CC
it_PIT
may_POMD [SPAU]
now_TIME
also_RB
be_VB [BEMA]
possible_PRED
to_TO
obtain_VB
income_NN
tax_NN
relief_NN
on_PIN
the_DT
donation_NOMZ
._.
Further_JJ
information_NOMZ
about_IN
ShareGift_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
on_PIN
its_PIT
website_NN
,_,
www_NN
._.
org_NN
,_,
or_CC
by_PIN
contacting_VBG
ShareGift_NN
on_PIN
020 7337 0501_CD
or_CC
at_PIN
46_CD
Grosvenor_NN
Street_NN
,_,
London_NN
W1K_NN
3HN_NN
._.
More_EMPH
information_NOMZ
about_IN
the_DT
tax_NN
position_NOMZ
on_PIN
gifts_NN
of_PIN
shares_NN
to_PIN
ShareGift_NN
can_POMD
be_VB [PASS]
obtained_VBN
from_PIN
the_DT
Inland_NN
Revenue_NN
whose_WPS [WHOBJ]
website_JJ
address_NN
is_VPRT
www_NN
._.
The_DT
share_NN
transfer_NN
form_NN
needed_VBN
to_TO
make_VB
a_DT
donation_NOMZ
may_POMD
be_VB [PASS]
obtained_VBN
from_PIN
the_DT
AstraZeneca_NN
Registrar_NN
,_,
Lloyds_NN
TSB_NN
Registrars_NN
whose_WPS [WHOBJ]
address_NN
can_POMD
be_VB [PASS]
found_VBN [PRIV]
on_PIN
the_DT
back_JJ
cover_NN
of_PIN
this_DEMO
document_NOMZ
._.
ShareGift_NN
is_VPRT [BYPA]
administered_VBN
by_PIN
The_DT
Orr_NN
Mackintosh_NN
Foundation_NOMZ
,_,
registered_VBD
charity_NOMZ
number_NN
1052686_CD
._.
The_DT
Unclaimed_NN
Assets_NN
Register_NN
AstraZeneca_NN
supplies_VPRT
unclaimed_JJ
dividend_NN
data_NN
to_PIN
the_DT
Unclaimed_NN
Assets_NN
Register_NN
UAR_NN
which_WDT [WHSUB]
provides_VPRT
investors_NN
who_WP [WHSUB]
have_VPRT [PEAS]
lost_VBN
track_NN
of_PIN
shareholdings_GER
with_PIN
an_DT
opportunity_NOMZ
to_TO
search_VB
the_DT
UARs_NN
database_NN
of_PIN
unclaimed_JJ
financial_JJ
assets_NN
on_PIN
payment_NOMZ
of_PIN
a_DT
small_JJ
,_,
fixed_JJ
fee_NN
._.
The_DT
UAR_NN
donates_VPRT
part_NN
of_PIN
the_DT
search_NN
fee_NN
to_PIN
charity_NOMZ
._.
The_DT
UAR_NN
can_POMD
be_VB [PASS]
contacted_VBN
at_PIN
Leconfield_NN
House_NN
,_,
Curzon_NN
Street_NN
,_,
London_NN
W1J_NN
5JA_NN
and_CC
at_PIN
www_NN
._.
Results_NN
Unaudited_JJ
trading_GER
results_NN
of_PIN
AstraZeneca_NN
in_PIN
respect_NN
of_PIN
the_DT
first_JJ
three_CD
months_NN
of_PIN
2004_CD
will_PRMD
be_VB [PASS]
published_VBN
on_PIN
29_CD
April_NN
2004_CD
and_CC
results_NN
in_PIN
respect_NN
of_PIN
the_DT
first_JJ
six_CD
months_NN
of_PIN
2004_CD
will_PRMD
be_VB [PASS]
published_VBN
on_PIN
22_CD
July_NN
2004_CD
._.
Documents_NOMZ
on_PIN
display_NN
The_DT
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
of_PIN
the_DT
Company_NN
and_CC
other_JJ
documents_NOMZ
concerning_VBG [WZPRES]
the_DT
Company_NN
which_WDT [WHSUB]
are_VPRT [PASS]
referred_VBN
to_PIN
in_PIN
this_DEMO
document_NOMZ
may_POMD
be_VB [PASS]
inspected_VBN
at_PIN
the_DT
Companys_NN
registered_VBD
office_NN
at_PIN
15_CD
Stanhope_NN
Gate_NN
,_,
London_NN
W1K_NN
1LN_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Shareholder_NN
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
131_CD
Taxation_NOMZ
for_PIN
US_FPP1
residents_NN
The_DT
following_JJ
summary_NN
of_PIN
the_DT
material_NN
UK_NN
and_CC
certain_JJ
US_FPP1
tax_NN
consequences_NN
of_PIN
ownership_NN
of_PIN
Ordinary_NN
Shares_NN
or_CC
ADRs_NN
held_VBD [PRIV]
as_IN
capital_NN
assets_NN
by_PIN
US_FPP1
resident_NN
shareholders_NN
is_VPRT [PASS]
based_VBN
on_PIN
current_JJ
UK_NN
and_PHC
US_FPP1
federal_JJ
income_NN
tax_NN
law_NN
,_,
including_VBG [PRESP]
the_DT
new_JJ
US_FPP1
UK_NN
double_JJ
taxation_NOMZ
convention_NOMZ
relating_VBG [WZPRES]
to_PIN
income_NN
and_PHC
capital_NN
gains_NN
,_,
which_WDT [SERE]
entered_VBD
into_PIN
force_NN
on_PIN
31_CD
March_NN
2003_CD
the_DT
Convention_NOMZ
and_CC
the_DT
prior_JJ
US_FPP1
UK_NN
double_JJ
taxation_NOMZ
convention_NOMZ
relating_VBG [WZPRES]
to_PIN
income_NN
and_PHC
capital_NN
gains_NN
the_DT
Prior_RB
Convention_NOMZ
,_,
and_ANDC
practice_NN
._.
This_DEMO
discussion_NN
is_VPRT [SPAU] [PASS]
also_RB
based_VBN
in_PIN
part_NN
on_PIN
representations_NOMZ
of_PIN
JPMorgan_NN
Chase_NN
Bank_NN
as_IN
Depositary_NN
for_PIN
ADRs_NN
and_CC
assumes_VPRT [PRIV]
that_THVC
each_QUAN
obligation_NOMZ
in_PIN
the_DT
deposit_NN
agreement_NOMZ
among_PIN
the_DT
Company_NN
,_,
the_DT
Depositary_NN
and_CC
the_DT
holders_NN
from_PIN
time_NN
to_PIN
time_NN
of_PIN
ADRs_NN
and_CC
any_QUAN
related_JJ
agreement_NOMZ
will_PRMD
be_VB [PASS]
performed_VBN
in_PIN
accordance_NN
with_PIN
its_PIT
terms_NN
._.
The_DT
US_FPP1
Treasury_NN
has_VPRT [PEAS]
expressed_VBN
concerns_NN
that_TOBJ
parties_NN
to_PIN
whom_WP [PIRE]
ADRs_NN
are_VPRT [BEMA]
pre-released_PRED
may_POMD
be_VB
taking_VBG
actions_NOMZ
that_TSUB
are_VPRT [BEMA]
inconsistent_PRED
with_PIN
the_DT
claiming_VBG [PUBV]
,_,
by_PIN
US_FPP1
holders_NN
of_PIN
ADRs_NN
,_,
of_PIN
foreign_JJ
tax_NN
credits_NN
for_PIN
US_FPP1
federal_JJ
income_NN
tax_NN
purposes_NN
._.
Accordingly_RB
,_,
the_DT
analysis_NN
of_PIN
the_DT
creditability_NOMZ
of_PIN
UK_NN
taxes_NN
described_VBD
below_PLACE
could_POMD
be_VB [BYPA]
affected_VBN
by_PIN
future_JJ
actions_NOMZ
that_TSUB
may_POMD
be_VB [BYPA]
taken_VBN
by_PIN
the_DT
US_FPP1
Treasury_NN
._.
UK_NN
and_PHC
US_FPP1
income_NN
taxes_NN
and_PHC
tax_NN
treaties_NN
affecting_VBG [WZPRES]
remittance_NN
of_PIN
dividends_NN
Under_IN
the_DT
Prior_RB
Convention_NOMZ
,_,
US_FPP1
resident_NN
individuals_NN
who_WP [WHSUB]
were_VBD [BEMA]
the_DT
beneficial_JJ
owners_NN
of_PIN
dividends_NN
on_PIN
Ordinary_NN
Shares_NN
,_,
or_CC
ADRs_NN
representing_VBG [WZPRES]
Ordinary_NN
Shares_NN
,_,
in_PIN
UK_NN
corporations_NOMZ
were_VBD [SPAU] [PASS]
generally_RB
entitled_VBN
to_PIN
a_DT
tax_NN
credit_NN
payment_NOMZ
in_PIN
respect_NN
of_PIN
dividends_NN
equal_JJ
to_PIN
one-ninth_JJ
1_CD
9th_CD
of_PIN
the_DT
dividend_NN
paid_VBD
the_DT
Tax_NN
Credit_NN
Amount_NN
._.
This_DEMO
tax_NN
credit_NN
payment_NOMZ
was_VBD [BYPA]
reduced_VBN
by_PIN
a_DT
UK_NN
withholding_VBG [WZPRES]
the_DT
UK_NN
withholding_GER
of_PIN
up_RB
to_PIN
15_CD
%_NN
of_PIN
the_DT
gross_JJ
dividend_NN
paid_VBN
._.
Therefore_CONJ
,_,
a_DT
US_FPP1
holder_NN
would_PRMD
not_XX0
actually_RB
receive_VB
any_QUAN
payment_NOMZ
of_PIN
this_DEMO
credit_NN
._.
US_FPP1
resident_JJ
corporate_JJ
shareholders_NN
are_VPRT [SPAU] [PASS]
generally_RB
treated_VBN
in_PIN
the_DT
same_JJ
way_NN
as_IN
individuals_NN
provided_VBD
that_DEMO
either_CC
alone_RB
,_,
or_CC
together_RB
with_PIN
associated_VBN
corporations_NOMZ
,_,
they_TPP3
do_VPRT
not_XX0
control_VB
directly_RB
or_CC
indirectly_RB
10_CD
%_NN
or_CC
more_EMPH
of_PIN
the_DT
voting_NN
shares_NN
of_PIN
the_DT
Company_NN
and_CC
do_VB
not_XX0
constitute_VB
investment_NOMZ
or_CC
holding_VBG [PRIV]
companies_NN
,_,
25_CD
%_NN
or_CC
more_EMPH
of_PIN
the_DT
capital_NN
of_PIN
which_WDT [PIRE]
is_VPRT [PASS]
owned_VBN
,_,
directly_RB
or_CC
indirectly_RB
,_,
by_PIN
persons_NN
that_TSUB
are_VPRT
not_XX0
individuals_NN
resident_NN
in_PIN [STPR]
,_,
and_ANDC
are_VPRT
not_XX0
nationals_NN
of_PIN [STPR]
,_,
the_DT
US_FPP1
._.
Under_IN
the_DT
Convention_NOMZ
,_,
US_FPP1
resident_NN
shareholders_NN
are_VPRT [SPAU] [PASS]
no_RB
longer_RB
entitled_VBN
to_PIN
the_DT
Tax_NN
Credit_NN
Amount_NN
because_CAUS
the_DT
Convention_NOMZ
does_VPRT
not_XX0
provide_VB
for_PIN
that_DEMO
entitlement_NOMZ
._.
The_DT
Convention_NOMZ
applies_VPRT
to_PIN
dividend_NN
payments_NOMZ
after_IN
1_CD
May_POMD
2003_CD
._.
However_CONJ
,_,
if_COND
a_DT
US_FPP1
resident_NN
shareholder_NN
would_PRMD
have_VB [PEAS]
been_VBN [PASS]
entitled_VBN
to_PIN
greater_JJ
benefits_NN
under_IN
the_DT
Prior_RB
Convention_NOMZ
,_,
the_DT
US_FPP1
resident_NN
shareholder_NN
may_POMD
elect_VB
to_TO
continue_VB
to_TO
apply_VB
the_DT
Prior_RB
Convention_NOMZ
until_IN
1_CD
May_POMD
2004_CD
._.
For_PIN
US_FPP1
federal_JJ
income_NN
tax_NN
purposes_NN
,_,
the_DT
dividend_NN
paid_VBN
and_CC
,_,
if_COND
a_DT
US_FPP1
resident_NN
shareholder_NN
elects_VPRT
under_IN
the_DT
Prior_RB
Convention_NOMZ
to_TO
claim_VB [PUBV]
a_DT
foreign_JJ
tax_NN
credit_NN
with_PIN
respect_NN
to_PIN
the_DT
UK_NN
withholding_GER
,_,
the_DT
associated_VBN
Tax_NN
Credit_NN
Amount_NN
are_VPRT [BEMA]
includible_PRED
in_PIN
gross_JJ
income_NN
by_PIN
US_FPP1
resident_NN
shareholders_NN
and_CC
,_,
for_PIN
foreign_JJ
tax_NN
credit_NN
limitation_NOMZ
purposes_NN
,_,
are_VPRT [BEMA]
foreign_JJ
source_NN
income_NN
,_,
treated_VBN [PASTP]
separately_RB
,_,
together_RB
with_PIN
other_JJ
items_NN
of_PIN
passive_JJ
income_NN
or_CC
,_,
in_PIN
the_DT
case_NN
of_PIN
certain_JJ
holders_NN
,_,
financial_JJ
services_NN
income_NN
._.
The_DT
UK_NN
withholding_GER
is_VPRT [PASS]
treated_VBN
as_IN
a_DT
foreign_JJ
income_NN
tax_NN
which_WDT [WHSUB]
may_POMD
,_,
subject_JJ
to_PIN
certain_JJ
limitations_NOMZ
and_PHC
restrictions_NOMZ
,_,
be_VB [BEMA]
eligible_PRED
for_PIN
credit_NN
against_PIN
a_DT
US_FPP1
resident_NN
shareholders_NN
US_FPP1
federal_JJ
income_NN
tax_NN
liability_NOMZ
or_CC
deductible_JJ
by_PIN
such_JJ
shareholders_NN
in_PIN
computing_VBG
their_TPP3
taxable_JJ
income_NN
for_PIN
a_DT
US_FPP1
resident_NN
shareholder_NN
who_WP [WHSUB]
elects_VPRT
to_TO
include_VB
the_DT
associated_VBN
Tax_NN
Credit_NN
Amount_NN
in_PIN
income_NN
._.
Under_IN
recently_TIME
enacted_VBN
US_FPP1
legislation_NOMZ
,_,
dividends_NN
received_VBN [WZPAST]
by_PIN
US_FPP1
resident_NN
non-corporate_JJ
holders_NN
of_PIN
Ordinary_NN
Shares_NN
or_CC
ADRs_NN
may_POMD
be_VB [BEMA]
subject_PRED
to_PIN
US_FPP1
federal_JJ
income_NN
tax_NN
at_PIN
lower_JJ
rates_NN
than_PIN
other_JJ
types_NN
of_PIN
ordinary_JJ
income_NN
if_COND
certain_JJ
conditions_NOMZ
are_VPRT [PASS]
met_VBN
._.
US_FPP1
resident_NN
shareholders_NN
should_NEMD
consult_VB
their_TPP3
own_JJ
tax_NN
advisors_NN
regarding_VBG [WZPRES]
the_DT
applications_NOMZ
of_PIN
this_DEMO
new_JJ
legislation_NOMZ
to_PIN
their_TPP3
particular_JJ
circumstances_NN
._.
Taxation_NOMZ
on_PIN
capital_NN
gains_NN
Under_IN
the_DT
Convention_NOMZ
each_QUAN
contracting_GER
state_NN
may_POMD
in_PIN
general_JJ
tax_NN
capital_NN
gains_NN
in_PIN
accordance_NN
with_PIN
the_DT
provisions_NN
of_PIN
its_PIT
domestic_JJ
law_NN
._.
Under_IN
present_JJ
UK_NN
law_NN
,_,
individuals_NN
who_WP [WHSUB]
are_VPRT [BEMA]
neither_SYNE
resident_NN
nor_SYNE
ordinarily_RB
resident_NN
in_PIN
the_DT
UK_NN
,_,
and_ANDC
companies_NN
which_WDT [WHSUB]
are_VPRT [BEMA]
not_XX0
resident_PRED
in_PIN
the_DT
UK_NN
will_PRMD
not_XX0
be_VB [BEMA]
liable_PRED
to_PIN
UK_NN
tax_NN
on_PIN
capital_NN
gains_NN
made_VBN [WZPAST]
on_PIN
the_DT
disposal_NN
of_PIN
their_TPP3
Ordinary_NN
Shares_NN
or_CC
ADRs_NN
,_,
unless_COND
such_JJ
Ordinary_NN
Shares_NN
or_CC
ADRs_NN
are_VPRT [PASS]
held_VBN [PRIV]
in_PIN
connection_NOMZ
with_PIN
a_DT
trade_NN
,_,
profession_NN
or_CC
vocation_NOMZ
carried_VBD
on_PIN
in_PIN
the_DT
UK_NN
through_PIN
a_DT
branch_NN
or_CC
agency_NN
._.
A_DT
US_FPP1
resident_NN
shareholder_NN
will_PRMD
recognize_VB [PRIV]
a_DT
capital_NN
gain_NN
or_CC
loss_NN
for_PIN
US_FPP1
federal_JJ
income_NN
tax_NN
purposes_NN
on_PIN
the_DT
sale_NN
or_CC
exchange_NN
of_PIN
the_DT
Ordinary_NN
Shares_NN
or_CC
ADRs_NN
in_PIN
the_DT
same_JJ
manner_NN
as_IN
such_JJ
holder_NN
would_PRMD
on_PIN
the_DT
sale_NN
or_CC
exchange_NN
of_PIN
any_QUAN
other_JJ
shares_NN
held_VBD [PRIV]
as_IN
capital_NN
assets_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
a_DT
US_FPP1
resident_NN
shareholder_NN
will_PRMD [SPAU]
generally_RB
recognize_VB [PRIV]
a_DT
capital_NN
gain_NN
or_CC
loss_NN
for_PIN
US_FPP1
federal_JJ
income_NN
tax_NN
purposes_NN
equal_JJ
to_PIN
the_DT
difference_NN
between_PIN
the_DT
amount_NN
realized_VBD [PRIV]
and_CC
such_JJ
holders_NN
adjusted_VBN
basis_NN
in_PIN
the_DT
Ordinary_NN
Shares_NN
or_CC
ADRs_NN
._.
The_DT
gain_NN
or_CC
loss_NN
will_PRMD [SPAU]
generally_RB
be_VB [BEMA]
US_FPP1
source_NN
income_NN
or_CC
loss_NN
._.
US_FPP1
resident_NN
shareholders_NN
should_NEMD
consult_VB
their_TPP3
own_JJ
tax_NN
advisors_NN
about_IN
the_DT
treatment_NOMZ
of_PIN
capital_NN
gains_NN
,_,
which_WDT [SERE]
may_POMD
be_VB [PASS]
taxed_VBN
at_PIN
lower_JJ
rates_NN
than_PIN
ordinary_JJ
income_NN
for_PIN
non-corporate_JJ
taxpayers_NN
and_PHC
capital_NN
losses_NN
,_,
the_DT
deductibility_NOMZ
of_PIN
which_WDT [PIRE]
may_POMD
be_VB [PASS]
limited_VBN
._.
UK_NN
inheritance_NN
tax_NN
Under_IN
the_DT
current_JJ
Double_RB
Taxation_NOMZ
Estates_NN
Convention_NOMZ
the_DT
Estate_NN
Tax_NN
Convention_NOMZ
between_PIN
the_DT
US_FPP1
and_CC
the_DT
UK_NN
,_,
Ordinary_NN
Shares_NN
or_CC
ADRs_NN
held_VBN [PRIV] [WZPAST]
by_PIN
an_DT
individual_JJ
shareholder_NN
who_WP [WHSUB]
is_VPRT [PASS]
domiciled_VBN
for_PIN
the_DT
purposes_NN
of_PIN
the_DT
Estate_NN
Tax_NN
Convention_NOMZ
in_PIN
the_DT
US_FPP1
,_,
and_ANDC
is_VPRT [BEMA]
not_XX0
for_PIN
the_DT
purposes_NN
of_PIN
the_DT
Estate_NN
Tax_NN
Convention_NOMZ
a_DT
national_JJ
of_PIN
the_DT
UK_NN
,_,
will_PRMD
generally_RB
not_XX0
be_VB [BEMA]
subject_PRED
to_PIN
the_DT
UK_NN
inheritance_NN
tax_NN
on_PIN
the_DT
individuals_NN
death_NN
or_CC
on_PIN
a_DT
chargeable_JJ
gift_NN
of_PIN
the_DT
Ordinary_NN
Shares_NN
or_CC
ADRs_NN
during_PIN
the_DT
individuals_NN
lifetime_NN
provided_VBD
that_DEMO
any_QUAN
applicable_JJ
US_FPP1
federal_JJ
gift_NN
or_CC
estate_NN
tax_NN
liability_NOMZ
is_VPRT [PASS]
paid_VBN
,_,
unless_COND
the_DT
Ordinary_NN
Shares_NN
or_CC
ADRs_NN
are_VPRT
part_NN
of_PIN
the_DT
business_NOMZ
property_NN
of_PIN
a_DT
permanent_JJ
establishment_NOMZ
of_PIN
the_DT
individual_NN
in_PIN
the_DT
UK_NN
or_CC
,_,
in_PIN
the_DT
case_NN
of_PIN
a_DT
shareholder_NN
who_WP [WHSUB]
performs_VPRT
independent_JJ
personal_JJ
services_NN
,_,
pertain_NN
to_PIN
a_DT
fixed_VBN
base_NN
situated_VBN [WZPAST]
in_PIN
the_DT
UK_NN
._.
Where_RB
the_DT
ADRs_NN
or_CC
Ordinary_NN
Shares_NN
have_VPRT [PEAS]
been_VBN [PASS]
placed_VBN
in_PIN
trust_NN
by_PIN
a_DT
settlor_NN
who_WP [WHOBJ]
,_,
at_PIN
the_DT
time_NN
of_PIN
settlement_NOMZ
,_,
was_VBD [BEMA]
a_DT
US_FPP1
resident_NN
shareholder_NN
,_,
the_DT
ADRs_NN
or_CC
Ordinary_NN
Shares_NN
will_PRMD
generally_RB
not_XX0
be_VB [BEMA]
subject_PRED
to_PIN
UK_NN
inheritance_NN
tax_NN
unless_COND
the_DT
settlor_NN
,_,
at_PIN
the_DT
time_NN
of_PIN
settlement_NOMZ
,_,
was_VBD [PASS]
not_XX0
domiciled_VBN
in_PIN
the_DT
US_FPP1
and_CC
was_VBD [BEMA]
a_DT
UK_NN
national_JJ
._.
In_PIN
the_DT
exceptional_JJ
case_NN
where_RB
the_DT
Ordinary_NN
Shares_NN
or_CC
ADRs_NN
are_VPRT [BEMA]
subject_PRED
both_DT
to_PIN
UK_NN
inheritance_NN
tax_NN
and_CC
to_PIN
US_FPP1
federal_JJ
gift_NN
or_CC
estate_NN
tax_NN
,_,
the_DT
Estate_NN
Tax_NN
Convention_NOMZ
generally_RB
provides_VPRT
for_PIN
double_JJ
taxation_NOMZ
to_TO
be_VB [BYPA]
relieved_VBN
by_PIN
means_NN
of_PIN
credit_NN
relief_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Shareholder_NN
Information_NOMZ
132_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Shareholder_NN
Information_NOMZ
continued_VBD
Exchange_NN
controls_NN
and_CC
other_JJ
limitations_NOMZ
affecting_VBG [WZPRES]
security_NOMZ
holders_NN
a_DT
There_EX
are_VPRT
no_SYNE
governmental_JJ
laws_NN
,_,
decrees_NN
or_CC
regulations_NOMZ
in_PIN
the_DT
UK_NN
restricting_VBG [WZPRES]
the_DT
import_NN
or_CC
export_NN
of_PIN
capital_NN
or_CC
affecting_VBG
the_DT
remittance_NN
of_PIN
dividends_NN
,_,
interest_NN
or_CC
other_JJ
payments_NOMZ
to_PIN
non-resident_JJ
holders_NN
of_PIN
Ordinary_NN
Shares_NN
or_CC
ADRs_NN
._.
However_CONJ
,_,
a_DT
1.5_CD
%_NN
stamp_NN
duty_NN
reserve_NN
tax_NN
is_VPRT [BEMA]
payable_PRED
upon_PIN
the_DT
deposit_NN
of_PIN
Ordinary_NN
Shares_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
creation_NOMZ
of_PIN [STPR]
,_,
but_CC
not_XX0
subsequent_JJ
dealing_GER
in_PIN [STPR]
,_,
ADRs_NN
._.
This_DEMP
is_VPRT [BEMA]
in_PIN
lieu_NN
of_PIN
the_DT
normal_JJ
0.5_CD
%_NN
stamp_NN
duty_NN
on_PIN
all_QUAN
purchases_NN
of_PIN
Ordinary_NN
Shares_NN
._.
b_NN
There_EX
are_VPRT
no_SYNE
limitations_NOMZ
under_IN
English_JJ
law_NN
or_CC
the_DT
Companys_NN
Memorandum_NN
and_PHC
Articles_NN
of_PIN
Association_NOMZ
on_PIN
the_DT
right_NN
of_PIN
non-resident_JJ
or_CC
foreign_JJ
owners_NN
to_TO
be_VB [BEMA]
the_DT
registered_VBN
holders_NN
of_PIN
and_CC
to_TO
vote_VB [SUAV]
Ordinary_NN
Shares_NN
or_CC
to_TO
be_VB [PASS]
registered_VBN
holders_NN
of_PIN
notes_NN
or_CC
debentures_NN
of_PIN
Zeneca_NN
Wilmington_NN
Inc._NN
or_CC
AstraZeneca_NN
PLC._NN
._.
Exchange_NN
rates_NN
For_PIN
the_DT
periods_NN
up_IN
to_PIN
April_NN
1999_CD
,_,
Astra_NN
accounted_VBD
for_PIN
and_CC
reported_VBD [PUBV]
its_PIT
results_NN
in_PIN
Swedish_JJ
kronor_NN
,_,
whereas_OSUB
Zeneca_NN
accounted_VBD
for_PIN
and_CC
reported_VBD [PUBV]
its_PIT
results_NN
in_PIN
sterling_GER
._.
Consistent_JJ
with_PIN
AstraZenecas_NN
decision_NN
to_TO
publish_VB
its_PIT
Financial_NN
Statements_NOMZ
in_PIN
US_FPP1
dollars_NN
,_,
the_DT
financial_JJ
information_NOMZ
in_PIN
this_DEMO
document_NOMZ
has_VPRT [PEAS]
been_VBN [PASS]
translated_VBN
from_PIN
kronor_NN
and_PHC
sterling_GER
into_PIN
US_FPP1
dollars_NN
at_PIN
the_DT
following_VBG
applicable_JJ
exchange_NN
rates_NN
:_:
SEK_NN
USD_NN
USD_NN
GBP_NN
Average_JJ
rates_NN
profit_NN
and_PHC
loss_NN
account_NN
,_,
cash_NN
flow_NN
1995_CD
7.1100_CD
1.5796_CD
1996_CD
6.7000_CD
1.5525_CD
1997_CD
7.6225_CD
1.6386_CD
1998_CD
7.9384_CD
1.6603_CD
1999_CD
8.2189_CD
1.6247_CD
End_NN
of_PIN
year_NN
spot_NN
rates_NN
balance_VPRT
sheet_NN
1995_CD
6.6500_CD
1.5500_CD
1996_CD
6.8400_CD
1.6900_CD
1997_CD
7.8500_CD
1.6600_CD
1998_CD
8.0400_CD
1.6600_CD
1999_CD
8.5130_CD
1.6185_CD
The_DT
following_VBG
information_NOMZ
relating_VBG [WZPRES]
to_PIN
average_JJ
and_CC
spot_NN
exchange_NN
rates_NN
used_VBN [WZPAST]
by_PIN
AstraZeneca_NN
is_VPRT [PASS]
provided_VBN
for_PIN
convenience_NN
:_:
SEK_NN
USD_NN
USD_NN
GBP_NN
Average_JJ
rates_NN
profit_NN
and_PHC
loss_NN
account_NN
,_,
cash_NN
flow_NN
2001_CD
10.3235_CD
1.4447_CD
2002_CD
9.8558_CD
1.4817_CD
2003_CD
8.3013_CD
1.6233_CD
End_NN
of_PIN
year_NN
spot_NN
rates_NN
balance_VPRT
sheet_NN
2001_CD
10.5420_CD
1.4501_CD
2002_CD
8.7700_CD
1.6093_CD
2003_CD
7.1932_CD
1.7815_CD
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Shareholder_NN
Information_NOMZ
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
133_CD
Definitions_NOMZ
In_PIN
this_DEMO
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
Information_NOMZ
the_DT
following_JJ
words_NN
and_PHC
expressions_NN
shall_PRMD
,_,
unless_COND
the_DT
context_NN
otherwise_CONJ
requires_VPRT [SUAV]
,_,
have_VPRT
the_DT
following_VBG
meanings_GER
:_:
ADR_NN
American_NN
Depositary_NN
Receipt_NN
evidencing_VBG [WZPRES]
title_NN
to_PIN
an_DT
ADS_NN
ADS_NN
American_NN
Depositary_NN
Share_NN
representing_VBG [WZPRES]
one_CD
underlying_VBG
Ordinary_NN
Share_NN
Depositary_NN
JPMorgan_NN
Chase_NN
Bank_NN
,_,
as_IN
depositary_NN
under_IN
the_DT
deposit_NN
agreement_NOMZ
pursuant_JJ
to_PIN
which_WDT [PIRE]
the_DT
ADRs_NN
are_VPRT [PASS]
issued_VBN
Directors_NN
The_DT
Directors_NN
of_PIN
the_DT
Company_NN
Company_NN
AstraZeneca_NN
PLC_NN
AstraZeneca_NN
,_,
AstraZeneca_NN
Group_NN
or_CC
the_DT
Group_NN
The_NN
Company_NN
and_CC
its_PIT
subsidiaries_NN
Ordinary_NN
Shares_NN
Ordinary_NN
Shares_NN
of_PIN
$_$
0.25_CD
each_QUAN
in_PIN
the_DT
capital_NN
of_PIN
the_DT
Company_NN
LSE_NN
London_NN
Stock_NN
Exchange_NN
Limited_NN
NYSE_NN
New_NN
York_NN
Stock_NN
Exchange_NN
,_,
Inc._NN
._.
SSE_NN
Stockholm_NN
Stock_NN
Exchange_NN
Sterling_GER
,_,
GBP_NN
,_,
pence_NN
or_CC
p_VB
References_NN
to_PIN
UK_NN
currency_NN
SEK_NN
,_,
kronor_NN
,_,
krona_NN
References_NN
to_PIN
Swedish_JJ
currency_NN
UK_NN
United_NN
Kingdom_NN
of_PIN
Great_NN
Britain_NN
and_PHC
Northern_NN
Ireland_NN
US_FPP1
dollar_NN
,_,
US$_$
,_,
USD_NN
or_CC
$_$
References_NN
to_PIN
US_FPP1
currency_NN
US_FPP1
United_NN
States_NN
of_PIN
America_NN
FDA_NN
Food_NN
and_PHC
Drug_NN
Administration_NOMZ
of_PIN
the_DT
US_FPP1
Figures_NN
in_PIN
parentheses_NN
in_PIN
tables_NN
and_CC
financial_JJ
statements_NOMZ
are_VPRT [PASS]
used_VBN
to_TO
represent_VB
negative_JJ
numbers_NN
._.
Except_PIN
where_RB
otherwise_CONJ
indicated_VBN [PRIV]
,_,
figures_NN
included_VBD
in_PIN
this_DEMO
report_NN
relating_VBG [WZPRES]
to_PIN
pharmaceutical_JJ
product_NN
market_NN
sizes_NN
and_PHC
market_NN
shares_NN
are_VPRT [PASS]
obtained_VBN
from_PIN
syndicated_VBN
industry_NN
sources_NN
,_,
primarily_RB
IMS_NN
Health_NN
IMS_NN
,_,
a_DT
market_NN
research_NN
firm_NN
internationally_RB
recognized_VBN [PRIV]
by_PIN
the_DT
pharmaceutical_JJ
industry_NN
._.
The_DT
2003_CD
market_NN
share_NN
figures_NN
included_VBD
in_PIN
this_DEMO
report_NN
are_VPRT [PASS]
based_VBN
primarily_RB
on_PIN
data_NN
obtained_VBN [WZPAST]
from_PIN
an_DT
online_JJ
IMS_NN
database_NN
._.
IMS_NN
data_NN
may_POMD
differ_VB
from_PIN
that_DEMP
compiled_VBN
by_PIN
the_DT
Group_NN
with_PIN
respect_NN
to_PIN
its_PIT
own_JJ
products_NN
._.
Of_PIN
particular_JJ
significance_NN
in_PIN
this_DEMO
regard_NN
are_VPRT [BEMA]
the_DT
following_GER
:_:
1_CD
AstraZeneca_NN
publishes_VPRT
its_PIT
financial_JJ
results_NN
on_PIN
a_DT
financial_JJ
year_NN
and_CC
quarterly_JJ
interim_JJ
basis_NN
,_,
whereas_OSUB
IMS_NN
issues_VPRT
its_PIT
data_NN
on_PIN
a_DT
monthly_JJ
and_PHC
quarterly_JJ
basis_NN
:_:
2_CD
the_DT
online_NN
IMS_NN
database_NN
is_VPRT [PASS]
updated_VBN
quarterly_JJ
and_CC
uses_VPRT
the_DT
average_JJ
exchange_NN
rates_NN
for_PIN
the_DT
relevant_JJ
quarter_NN
:_:
3_CD
IMS_NN
data_NN
from_PIN
the_DT
US_FPP1
is_VPRT [PASS]
not_XX0
adjusted_VBN
for_PIN
Medicaid_NN
and_CC
similar_JJ
state_NN
rebates_NN
:_:
and_ANDC
4_CD
IMS_NN
sales_NN
data_NN
are_VPRT [PASS]
compiled_VBN
using_VBG
actual_JJ
wholesaler_NN
data_NN
and_PHC
data_NN
from_PIN
statistically_RB
representative_JJ
panels_NN
of_PIN
retail_JJ
and_CC
hospital_NN
pharmacies_NN
,_,
which_WDT [SERE]
data_NN
are_VPRT [SPAU] [BYPA]
then_RB
projected_VBN
by_PIN
IMS_NN
to_TO
give_VB
figures_NN
for_PIN
national_JJ
markets_NN
._.
References_NN
to_PIN
prevalence_NN
of_PIN
disease_NN
have_VPRT [PEAS]
been_VBN [PASS]
derived_VBN
from_PIN
a_DT
variety_NN
of_PIN
sources_NN
and_CC
are_VPRT [PASS]
not_XX0
intended_VBN [SUAV]
to_TO
be_VB [BEMA]
indicative_PRED
of_PIN
the_DT
current_JJ
market_NN
or_CC
any_QUAN
potential_JJ
market_NN
for_PIN
AstraZenecas_NN
pharmaceutical_JJ
products_NN
since_OSUB
,_,
among_PIN
other_JJ
things_NN
,_,
there_EX
may_POMD
be_VB
no_SYNE
correlation_NOMZ
between_PIN
the_DT
prevalence_NN
of_PIN
a_DT
disease_NN
and_CC
the_DT
number_NN
of_PIN
individuals_NN
who_WP [WHSUB]
are_VPRT [PASS]
treated_VBN
for_PIN
such_EMPH
a_NULL
disease_NN
._.
AstraZeneca_NN
Annual_JJ
Report_NN
and_PHC
Shareholder_NN
Information_NOMZ
134_CD
Form_NN
20-F_JJ
Information_NOMZ
2003_CD
Shareholder_NN
Information_NOMZ
continued_VBD
Terms_NN
used_VBN [WZPAST]
in_PIN
the_DT
Annual_JJ
Report_NN
and_PHC
Form_NN
20-F_JJ
Information_NOMZ
US_FPP1
equivalent_JJ
or_CC
brief_JJ
description_NOMZ
Accruals_NN
Accrued_VBN
expenses_NN
Allotted_NN
Issued_NN
Bank_NN
borrowings_GER
Payable_JJ
to_PIN
banks_NN
Called-up_JJ
share_NN
capital_NN
Issued_VBN
share_NN
capital_NN
Capital_NN
allowances_NN
Tax_NN
term_NN
equivalent_NN
to_PIN
US_FPP1
tax_NN
depreciation_NOMZ
allowances_NN
Creditors_NN
Liabilities_NOMZ
payables_NN
Current_JJ
instalments_NOMZ
of_PIN
loans_NN
Long_JJ
term_NN
debt_NN
due_JJ
within_PIN
one_CD
year_NN
Debtors_NN
Receivables_NN
and_CC
prepaid_JJ
expenses_NN
Earnings_GER
Net_JJ
income_NN
Finance_NN
lease_NN
Capital_NN
lease_NN
Fixed_VBN
asset_NN
investments_NOMZ
Non-current_JJ
investments_NOMZ
Freehold_NN
Ownership_NN
with_PIN
absolute_JJ
rights_NN
in_PIN
perpetuity_NOMZ
Interest_NN
receivable_NN
Interest_NN
income_NN
Interest_NN
payable_JJ
Interest_NN
expense_NN
Loans_VPRT
Long_JJ
term_NN
debt_NN
Prepayments_NOMZ
Prepaid_JJ
expenses_NN
Profit_NN
Income_NN
Profit_NN
and_PHC
loss_NN
account_NN
Income_NN
statement_NOMZ
consolidated_JJ
statement_NOMZ
of_PIN
income_NN
Reserves_NN
Retained_VBN
earnings_GER
Short_JJ
term_NN
investments_NOMZ
Redeemable_JJ
securities_NOMZ
and_CC
short_JJ
term_NN
deposits_NN
Share_NN
premium_NN
account_NN
Premiums_NN
paid_VBN [WZPAST]
in_PIN
excess_NN
of_PIN
par_JJ
value_NN
of_PIN
Ordinary_NN
Shares_NN
Statement_NOMZ
of_PIN
total_JJ
recognized_VBN [PRIV]
gains_NN
and_PHC
losses_NN
Statement_NOMZ
of_PIN
comprehensive_JJ
income_NN
Stocks_NN
Inventories_NN
Tangible_JJ
fixed_VBN
assets_NN
Property_NN
,_,
plant_NN
and_PHC
equipment_NOMZ
Turnover_NN
Sales_NN
revenues_NN
